drugset / Trial / NCT02468674
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
RandomizedSingle-groupQuadruple-blindTreatment
Summary
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
Timeline
- Start
- 2015-07-22
- Primary completion
- 2018-12-03
- Completion
- 2018-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimagrumab | Monoclonal antibody | 70 mg | Intravenous |
| Subject | Bimagrumab | Monoclonal antibody | 210 mg | Intravenous |
| Subject | Bimagrumab | Monoclonal antibody | 700 mg | Intravenous |